Drug Discovery & Pharmaceuticals

RSS

Restricted Interaction Peptides Change Shape to Lock Therapy Inside Solid Tumors

Medications are designed to treat diseased tissues while sparing healthy ones, often by attaching the drug to something that helps guide it directly to its target.

14 May 2026

Phesi Analysis of More Than 600,000 Clinical Trial Protocols Finds Less Than a Third are Linked to Patient Data

Phesi, a global provider of patient-centric data science solutions for clinical development, has conducted a global analysis of more than 600,000 clinical trial protocols ahead of ASCO 2026.

From Phesi 13 May 2026

Advanced Molecular Blueprints Guide Development Of Next-Generation Malaria Drugs

Researchers from the Universities of Bath and Leeds (UK) have made a significant advance in the fight against malaria by uncovering a promising new potential target for drug discovery.

7 May 2026

CapyBio Launches New Analysis Services to Improve Cell Identity Engineering

CapyBio, a cell identity tools and services company, today announced the launch of three new commercial analysis services: Capybara™ Benchmarking Analysis, Capybara Advanced Analysis, and CellOracle™ Differentiation Optimization Analysis.

7 May 2026

AI Designs New Antibiotics That Reduce MRSA Infections In Mice

SyntheMol-RL integrates reinforcement learning for antibiotic design, producing synthesizable candidates that show efficacy against MRSA in preclinical models.

5 May 2026

MRM Health’s Lead Candidate MH002 Granted Fast Track Designation by U.S. FDA for the Treatment of Mild-to-Moderate Ulcerative Colitis

MRM Health, a clinical-stage biopharmaceutical company developing therapeutics for immune-mediated diseases, which unlock the power of the microbiome to restore immune balance, today announced that MH002, the Company’s lead rationally designed Live Biotherapeutic Product (LBP) candidate, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate ulcerative colitis (UC).

From MRM Health NV 4 May 2026

New Pipeline Sharpens Single-Cell Profiling of CAR Immune Therapies

CERTOMICS is a Nextflow-based computational pipeline designed to identify and profile CAR-engineered immune cells using single-cell multiomics data. By integrating gene expression, immune receptor profiling, protein markers, CAR-aware references, and CAR-specific quality control, it supports more standardized analysis of adoptive cellular immunotherapies.

29 Apr 2026

Drug Development: Development of Dextran Nanoparticles for Stabilizing Delicate Proteins

Nanoscale Research Letters, an open access journal published under Springer Open, presented a study entitled "Development of Dextran Nanoparticles for Stabilizing Delicate Proteins." In this study, a Brookhaven NanoBrook 90Plus Particle Size Analyzer was used to help develop a novel approach to stabilize and encapsulate proteins into dextran nanoparticles.

From Brookhaven Instruments 29 Apr 2026

Generative AI Model Accelerates Drug Discovery With New Antibiotic Candidate

Researchers at McMaster University have developed a new generative artificial intelligence (AI) model capable of drastically speeding up drug discovery - and, in early tests, it has already designed a brand-new antibiotic.

24 Apr 2026

Fragment-Based Drug Design Accelerates Efficient Discovery of New Medicines

Modern medicine has played a significant role in improving the length and quality of our lives. While many treatments may seem like miracles, they are the result of a lengthy, rigorous research process.

24 Apr 2026

Scientists Uncover the Molecular Fingerprints of mRNA Vaccine-Induced T Cells

The advent of mRNA vaccines against SARS-CoV-2 in 2020 changed the course of the COVID-19 pandemic. Now, the Nobel-prize–winning technology is being adapted to fight cancer, with mRNA vaccines in clinical trials for melanoma, small cell lung cancer and bladder cancer, among others, opening the door to new ways of preventing and treating the disease.

17 Apr 2026

UTMB Researchers Develop AI Pipeline to Accelerate Pan-Alphavirus Vaccine Development

A team of scientists at The University of Texas Medical Branch (UTMB), led by Nikos Vasilakis, PhD, and Peter McCaffrey, MD, has developed a new computational pipeline that could dramatically accelerate the development of vaccines against a group of mosquito-borne viruses known as alphavirus.

11 Apr 2026

Cutting-Edge AI Tool Could Accelerate the Creation of New Medicines

University of Virginia School of Medicine scientists have developed a bold new approach to drug development and discovery that could dramatically accelerate the creation of new medicines.

10 Apr 2026

Semen-Derived Exosomes Eye Drops to Treat Retinoblastoma

Innovative eye drops using semen-derived exosomes target retinoblastoma, improving therapeutic delivery and preserving ocular function in preclinical models.

8 Apr 2026

Novel ENDOtollins Block Harmful Inflammation While Preserving Infection Response

Scripps Research scientists have developed a new class of drug compounds that reduce harmful inflammation while leaving the body's ability to fight infections intact-a long-sought goal in treating autoimmune diseases.

7 Apr 2026

PRISM ALS: New Stem Cell Models Could Transform Research into Treatments for MND/ALS

A new global initiative launched today aims to close a critical gap in ALS/MND drug discovery – current cell models used for testing treatments do not currently reflect the diverse nature of the disease – that affects both researchers developing therapies and the people urgently waiting for them.

From Axol Bioscience Ltd 2 Apr 2026

Shimadzu’s Design Craftech - Fusing Traditional Kyoto Craft Techniques with Industrial Production

Shimadzu Corporation, which was celebrating its 150th anniversary in 2025, has a long history of involvement with traditional Kyoto crafts dating back to its origins as a maker of Buddhist altar fittings.

From Shimadzu Europa GmbH 27 Mar 2026

EV Engineering Boosts Drug Delivery and Improves Sepsis Survival

The engineered scaffold protein EN144 significantly improves extracellular vesicle therapies, showing potential in sepsis treatment and targeted drug delivery.

18 Mar 2026

Solving a 50-year Bottleneck in Chemotherapy Drug Production

A multinational team of researchers has made a significant advance in the manufacturing of doxorubicin, a crucial chemotherapy drug.

16 Mar 2026

mAbxience Selects Genedata Bioprocess to Automate End-to-End CDMO Workflows

Genedata, a Danaher company and the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that mAbxience has selected the Genedata Bioprocess® enterprise platform to structure and harmonize all bioprocess development data across its operations.

From Genedata AG 11 Mar 2026